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BACKGROUND: There is no recommended therapy for malignant pleural
mesothelioma that has progressed after first-line pemetrexed and platinum-based
chemotherapy. Disease control has been less than 30% in all previous studies of
second-line drugs. Preliminary results have suggested that anti-programmed cell
death 1 (PD-1) monoclonal antibody could be efficacious in these patients. We thus
aimed to prospectively assess the anti-PD-1 monoclonal antibody alone or in
combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody in patients
with malignant pleural mesothelioma.
METHODS: This multicentre randomised, non-comparative, open-label, phase 2 trial
was done at 21 hospitals in France. Eligible patients were aged 18 years or older with
an Eastern Cooperative Oncology Group performance status of 0-1, histologically
proven malignant pleural mesothelioma progressing after first-line or second-line
pemetrexed and platinum-based treatments, measurable disease by CT, and life
expectancy greater than 12 weeks. Patients were randomly allocated (1:1) to receive
intravenous nivolumab (3 mg/kg bodyweight) every 2 weeks, or intravenous
nivolumab (3 mg/kg every 2 weeks) plus intravenous ipilimumab (1 mg/kg every 6
weeks), given until progression or unacceptable toxicity. Central randomisation was
stratified by histology (epithelioid vs non-epithelioid), treatment line (second line vs
third line), and chemosensitivity to previous treatment (progression ≥3 months vs <3
months after pemetrexed treatment) and used a minimisation method with a 0·8
random factor. The primary outcome was the proportion of patients who achieved 12-
week disease control, assessed by masked independent central review; the primary
endpoint would be met if disease control was achieved in at least 40% of patients. The
primary endpoint was assessed in the first 108 eligible patients. Efficacy analyses
were also done in the intention-to-treat population and safety analyses were done in
all patients who received at least one dose of their assigned treatment. This trial is
registered at ClinicalTrials.gov, number NCT02716272.
FINDINGS: Between March 24 and August 25, 2016, 125 eligible patients were
recruited and assigned to either nivolumab (n=63) or nivolumab plus ipilimumab
(n=62). In the first 108 eligible patients, 12-week disease control was achieved by 24
(44%; 95% CI 31-58) of 54 patients in the nivolumab group and 27 (50%; 37-63) of 54
patients in the nivolumab plus ipilimumab group. In the intention-to-treat population,
12-week disease control was achieved by 25 (40%; 28-52) of 63 patients in the
nivolumab group and 32 (52%; 39-64) of 62 patients in the combination group. Nine
(14%) of 63 patients in the nivolumab group and 16 (26%) of 61 patients in the
combination group had grade 3-4 toxicities. The most frequent grade 3 adverse
events were asthenia (one [2%] in the nivolumab group vs three [5%] in the
combination group), asymptomatic increase in aspartate aminotransferase or alanine
aminotransferase (none vs four [7%] of each), and asymptomatic lipase increase (two
[3%] vs one [2%]). No patients had toxicities leading to death in the nivolumab group,
whereas three (5%) of 62 in the combination group did (one fulminant hepatitis, one
encephalitis, and one acute kidney failure).
INTERPRETATION: Anti-PD-1 nivolumab monotherapy or nivolumab plus anti-CTLA-4
ipilimumab combination therapy both showed promising activity in relapsed patients
with malignant pleural mesothelioma, without unexpected toxicity. These regimens
require confirmation in larger clinical trials.
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